Cite

HARVARD Citation

    Reck, M. et al. (n.d.). Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Lung cancer. 90 (2), pp. 267-273. [Online]. 
  
Back to record